Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
168
datasets available to search
ShareScore release 0.9.0
Dataset results
168 results for “Pre-exposure prophylaxis”
Effect of pre-exposure prophylaxis with tenofovir disoproxil fumarate and emtricitabine on gene expression
GEO Series GSE139611. Homo sapiens. 64 samples. Type: Expression profiling by array.
Effect of pre-exposure prophylaxis with tenofovir disoproxil fumarate and emtricitabine on gene expression in the rectum
GEO Series GSE139610. Homo sapiens. 16 samples. Type: Expression profiling by array.
Data from: Understanding willingness to use oral pre-exposure prophylaxis for HIV prevention among men who have sex with men in China
Background: Oral pre-exposure prophylaxis (PrEP) is recommended as an additional prevention choice for men who have sex with men (MSM) at substantial risk of HIV. The aim of this study was to evaluate the extent, and reasons, for MSM's willingness to use oral PrEP in Wuhan and Shanghai, China. Methods: Between May and December 2015, a cross-sectional survey was conducted among 487 MSM recruited through snowball sampling in physical locations frequented by MSM and through social media applications. Exploratory factor analysis was used to group reasons for being willing or not willing to use PrEP. Chi-square tests were used to explore bivariate associations between groupings of reasons for being willing or unwilling to use PrEP, and key sociodemographic and sexual-behavioral characteristics of MSM. Results: Overall, 71.3% of respondents were willing to use PrEP. The most commonly reported reasons for being willing to use PrEP were preventing HIV infection (91.6%), taking responsibility for own sexual health (72.6%) and protecting family members from harm (59.4%). The main reasons for being unwilling to use PrEP were being worried about side effects (72.9%), the necessity of taking PrEP for long periods of time (54.3%) and cost (40.4%). Individual characteristics that influenced the type of reasons given for being willing or unwilling to use PrEP included being married to a woman, having a regular sex partner, rates of condom use with regular and casual sex partners, and the number of casual sex partners. Conclusion: The introduction of PrEP in China could benefit from promotion campaigns that emphasize its role in preventing HIV infection, in taking responsibility for own sexual health, and in protecting family members from potential harm. To reduce uptake barriers, it will be essential to provide accurate information to potential PrEP users about the mild and short-term nature of side effects, and the possibility of taking PrEP only during particular periods of life when the risk of HIV exposure might be highest.
Evaluation of Pre-Exposure Prophylaxis for High Risk Adolescent Girls and Young Women
ClinicalTrials.gov study NCT04044235. IPD Sharing: NO. Countries: 1. Publications: 0.
Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)
ClinicalTrials.gov study NCT07047716. IPD Sharing: NO. Countries: 1. Publications: 0.
Evaluation of Implementation of Pre-exposure Prophylaxis (PrEP) in Norway
ClinicalTrials.gov study NCT03436407. IPD Sharing: NO. Countries: 1. Publications: 0.
Decision Support Intervention Adapted for HIV Pre-Exposure Prophylaxis for Adoption and Adherence for Black Canadians
ClinicalTrials.gov study NCT03637244. IPD Sharing: NO. Countries: 1. Publications: 0.
Demonstrating Safety and Effective Delivery of Daily Oral Pre-exposure Prophylaxis (PrEP) for Sex Workers in India
ClinicalTrials.gov study NCT02148094. IPD Sharing: NO. Countries: 1. Publications: 0.
Delivery Optimization for Pre-Exposure Prophylaxis (DO PrEP) Study
ClinicalTrials.gov study NCT06176859. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women
ClinicalTrials.gov study NCT01749566. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Online Network Intervention to Increase HIV Pre-exposure Prophylaxis Intention
ClinicalTrials.gov study NCT04771312. IPD Sharing: NO. Countries: 1. Publications: 0.
Evaluating The Acceptability and Uptake of Pre-Exposure Prophylaxis (PrEP) for Adolescent Women in The Deep South
ClinicalTrials.gov study NCT03897725. IPD Sharing: YES. Countries: 1. Publications: 0.
PrEPared-RN, CAN Nurse-Led Management of High-risk Patients for Pre-Exposure Prophylaxis (PrEP)
ClinicalTrials.gov study NCT06030557. IPD Sharing: NO. Countries: 1. Publications: 0.
ALIGN: A Non-randomised Study Delivering Injectable Lenacapavir for HIV Prevention Within a Pre-exposure Prophylaxis (PrEP) Choice Context in Cape Town, South Africa.
ClinicalTrials.gov study NCT07390409. IPD Sharing: YES. Countries: 1. Publications: 0.
EASY-TESTS: Evaluation of the Acceptability of Pre-exposure Prophylaxis (PrEP) Among Men Who Have Sex With Men (MSM) Who Accepted Targeted HIV/STI Testing, Recruited Through a Community-based Outreach
ClinicalTrials.gov study NCT05949814. IPD Sharing: NO. Countries: 1. Publications: 0.
HIV Pre-exposure Prophylaxis Implementation Hong Kong Study
ClinicalTrials.gov study NCT04367688. IPD Sharing: NO. Countries: 1. Publications: 0.
Rectal Insert TAF/EVG Pre-Exposure Prophylaxis (RITE PrEP) Study
ClinicalTrials.gov study NCT06274398. IPD Sharing: NO. Countries: 1. Publications: 0.
Mhealth for Pre-exposure Prophylaxis Adherence by Young Adult MSM
ClinicalTrials.gov study NCT04233931. IPD Sharing: NO. Countries: 1. Publications: 0.
Evaluation of PrEP-30: a Demonstration Project of Pre-exposure Prophylaxis for MSM and Other High-risk Group Clients at the Thai Red Cross Anonymous Clinic
ClinicalTrials.gov study NCT02437981. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Pre-Exposure Prophylaxis Using TMC278LA
ClinicalTrials.gov study NCT01049932. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.